MDXG - MiMedx: Amniotic Hypotheses Create Decent Fundamental Momentum

• MiMedx Group is in the early stages of a sales recovery, after a turbulent last 2 years.
• 90% of management are new faces, and the new growth strategy dovetails to include commercialization, R&D focus and supply chain integration.
• Their amniotic hypotheses have high commercial potential, and the potential to create a remedial breakthrough and fulfil unsuccessful treatment voids.
• The AmnioFix segment has over $1.5 billion commercial opportunity by our analysis, in the conservative osteoarthritis treatment market.
• We see a fair value of $7.30 and believe further upside is likely on the back of recent fundamental momentum.

For further details see: